Patterns of Domperidone Prescribing for Breast Milk Stimulation in Lactating Women According to Rational Drug Use Criteria at a Mother and Child Hospital in Chiang Mai Province
Article Sidebar
Main Article Content
Abstract
Objective: 1) To examine patterns of domperidone prescribing for breast milk stimulation in lactating women according to the recommendation in handbook of the project on rational drug use hospitals and 2) To examine characteristics of lactating women and infants whose mothers received domperidone for breast milk stimulation. Methods: This was a cross-sectional study involving 394 lactating women delivering babies at a Mother and Child Hospital in Chiang Mai province during Oct. 1, 2013 and Sep. 30, 2015. The study collected the following data from patient records and electronic database within the hospital using the form developed in the study-pre-labored characteristics, type of delivery, child health, domperidone and other medication prescribing, and milk flow assessment. Results: The prevalence of domperidone prescribing for breast milk stimulation in lactating women was 8.9%. Pattern for first dose regimen of domperidone was 20 mg 4 times a day (80 mg/day) (82.9%). The prevalence of domperidone prescribing within 10 days after birth was 8.9%. Most subjects received the medication on the second day after child delivery (57.2%). Domperidone was prescribed continuously for 1 day and 2 in 42.9 % and 20 % of subjects. Most lactating women were prescribed domperidone while having milk flow. One lactating woman was prescribed domperidone with levothyroxine. Conclusions: We found a high rate of domperidone prescribing in lactating women for breast milk stimulation while in hospital after child delivery. Initial dose of domperidone was higher than 30 mg/day. Most lactating women were prescribed domperidone without an indication. Therefore, risk management should be implemented, and rational prescribing of domperidone should be promoted.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Topothai T, Thaijinda C, Cetthaakrikul N, Putthasri V, Boonthamcharoen K, Prakongsai P, et al. The study of the awareness of breastfeeding campaign and powdered milk advertising with knowledge, attitude and preparation for breastfeeding for mothers and relatives [online]. 2015 [cited May 10, 2015]. Available from: ihppthaigov.net/DB/publicati on/attachresearch/325/chapter1.pdf.
Gatti L. Maternal perceptions of insufficient milk supply in breastfeeding. J Nurs Scholarsh. 2008; 40: 355-63.
Bureau of Health Promotion, Department of Health, Ministry of Public Health. Training document “Breastfeeding”. Bangkok: The Agricultural Coope rative Federation of Thailand; 2546.
Academy of Breastfeeding Medicine Protocol C. ABM clinical protocol #7: model breastfeeding policy. Breastfeed Med. 2007; 2: 50-5.
Grzeskowiak LE, Lim SW, Thomas AE, Ritchie U, Gordon A. Audit of domperidone use as a galacto gogue at an Australian tertiary teaching hospital. J Hum Lact. 2013;29:32-7.
Mannion C, Mansell D. Breastfeeding self-efficacy and the use of prescription medication: a pilot study. Obstet Gynecol Int J. 2012; 2012: 562704.
Smolina K, Morgan SG, Hanley GE, Oberlander TF, Mintzes B. Postpartum domperidone use in British Columbia: a retrospective cohort study. CMAJ open. 2016; 4: E13-9.
Drugs and Lactation Database (LactMed) [Ionline]. Bethesda (MD): National Library of Medicine (US). [2018]. Domperidone; [rev. Jul 20, 2019; cited Jul 23, 19]; Available from: www.ncbi.nlm.nih.gov/ books/NBK501371/
Campbell-Yeo ML, Allen AC, Joseph KS, Ledwidqe JM, Caddell K, Allen VM, et al. Effect of domperi done on the composition of preterm human breast milk. Pediatrics. 2010; 125: e107-14.
Taylor A, Logan G, Twells L, Newhook LA. Human milk expression after domperidone treatment in postpartum women: a systematic review and meta-analysis of randomized controlled trials. J Hum Lact 2019; 35: 501-9.
da Silva OP, Knoppert DC, Angelini MM, Forret PA. Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo-controlled trial. CMAJ. 2001; 164: 17-21.
Wannapat M, Suthutvoravut S, Suwikrom S. Effectiveness of domperidone in augmenting breast milk production measured by manual expression in postpartum women in Charoenkrung Pracharak Hospital. Ramathibodi Medical Journal. 2018; 41: 17-26.
Grzeskowiak LE, Smithers LG, Amir LH, Grivell RM et al. Domperidone for increasing breast milk volume in mothers expressing breast milk for their preterm infants: a systematic review and meta-analysis. Obstet Gynecol Int J 2018; 125: 1371-78.
Donovan TJ, Buchanan K. Medications for increasing milk supply in mothers expressing breastmilk for their preterm hospitalised infants. Cochrane Database Syst Rev. 2012;3:CD005544.
Osadchy A, Moretti ME, Koren G. Effect of domperidone on insufficient lactation in puerperal women: a systematic review and meta-analysis of randomized controlled trials. Obstet Gynecol Int J. 2012; 2012: Article ID642893.
Brown TE, Fernandes PA, Grant LJ, Hutsul JA, McCoshen JA. Effect of parity on pituitary prolactin response to metoclopramide and domperidone: implications for the enhancement of lactation. J Soc Gynecol Investig. 2000; 7: 65-9.
Leelakanok N, Holcombe A, Schweizer ML. Dompe ridone and risk of ventricular arrhythmia and cardiac death: a systematic review and meta-analysis. Clin Drug Investig. 2016; 36: 97-107.
Marzi M, Weitz D, Avila A, Molina G, Caraballo L, Piskulic L. Cardiac adverse effects of domperidone in adult patients: a systematic review. Rev Med Chil. 2015; 143: 14-21.
Buffery PJ, Strother RM. Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations. N Z Med J. 2015; 128: 66-74.
Hill C, Nicot P, Piette C, Le Gleut K, Durand G, Toussaint B. Estimating the number of sudden cardiac deaths attributable to the use of domperi done in France. Pharmacoepidemiol Drug saf. 2015; 24: 543-7.
van Noord C, Dieleman JP, van Herpen G, Verha mme K, Sturkenboom MC. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010; 33: 1003-14.
Grzeskowiak LE, Smithers LG,Amir LH, Grivell RM. Domperidone for increasing breast milk volume in mothers expressing breast milk for their preterm infants: a systematic review and meta-analysis. Gynaecol Obstet Int J. 2018; 125: 1371-78.
Djeddi D, Kongolo G, Lefaix C, Mounard J, Leke A. Effect of domperidone on QT interval in neonates. J Pediatr. 2008ว 153: 663-66.
Rachuso S. Effectiveness of domperidone in breast milk production augmentation of term cesarean deliveries mothers. Buddhachinaraj Medical Journal 2009; 26: 168-72.
Paul C, Zenut M, Dorut A, Coudore MA, Vein J, Cardot JM, et al. Use of domperidone as a galacta gogue drug: a systematic review of the benefit-risk ratio. J Hum Lact. 2015;31:57-63.
Da Silva OP, Knoppert DC, Angelini MM, Forret PA. Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo-controlled trial. CMAJ. 2001; 164: 17-21.
Buffery PJ, Strother RM. Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations. N Z Med J. 2015; 128: 66-74.
Donovan TJ, Buchanan K. Medications for increa- sing milk supply in mothers expressing breastmilk for their preterm hospitalised infants. Cochrane Data base Syst Rev. 2012;3:CD005544.
Osadchy A, Moretti ME, Koren G. Effect of domperi done on insufficient lactation in puerperal women: a systematic review and meta-analysis of randomi zed controlled trials. Obstet Gynecol Int J. 2012; 2012: 642893.
Academy of Breastfeeding Medicine Protocol C. ABM Clinical Protocol #9: Use of galactogogues in initiating or augmenting the rate of maternal milk secretion (first revision January 2011). Breastfeed Med. 2011; 6:4 1-9.
Rational drug promotion sub-committee. Rational Drug Use Hospital Manual [online]. 2015 [cited Oct 10, 2015]. Available from: www.fda.moph.go.th /sites/drug/Shared%20Documents/National-Drug-Policy/06/RDU%20final_220615.pdf.
European Medicine Agency. PRAC recommends restricting use of domperidone [online]. 2014 [cited May 22, 2015]. Available from: www.ema.europa. eu/en/documents/press-release/prac-recommends-restricting-use-domperidone_enpdf.
Chetawan W, Wangpluk M. The use of domperidone to stimulate milk in breastfeeding clinic at health promoting hospital, health promotion region 10 Chiang Mai [online]. 2005 [cited May 22, 2015]. Available from: www.breastfeedingthai.com/galacta gogue-domperidone-motilium.html.
National Statistical Office, United Nations Children’s Fund, Thailand. Multiple indicator cluster survey 2015-2016, final report [online]. 2016 [cited May 4, 2018]. Available from: www.unicef.org/thailand/me dia/201/file/Thailand%20MICS%202015-2016%20 (full%20report).pdf.
Bozzo P, Koren G, Ito S. Health Canada advisory on domperidone: Should I avoid prescribing dompe ridone to women to increase milk production? Can Fam Physician. 2012; 58: 952-3.
Wan EW, Davey K, Page-Sharp M et al. Dose-effect study of domperidone as a galactagogue in preterm mothers with insufficient milk supply, and its transfer into milk. Br J Clin Pharmacol. 2008; 66: 283-9.
Knoppert DC, Page A, Warren J et al. The effect of two different domperidone dosages on maternal milk production. J Hum Lact. 2013;29:38-44.
